Cargando…

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2

OBJECTIVES: Metastatic melanoma patients with leptomeningeal disease (LMD) have an extremely poor prognosis, with a median survival measured in weeks, and few treatment options. Outcomes of a retrospective cohort of patients with LMD that were treated with intrathecal interleukin-2 (IT IL-2) were re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glitza, Isabella C, Rohlfs, Michelle, Guha-Thakurta, Nandita, Bassett, Roland L, Bernatchez, Chantale, Diab, Adi, Woodman, Scott E, Yee, Cassian, Amaria, Rodabe N, Patel, Sapna P, Tawbi, Hussein, Wong, Michael, Hwu, Wen-Jen, Hwu, Patrick, Heimberger, Amy, McCutcheon, Ian E, Papadopoulos, Nicholas, Davies, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786950/ https://www.ncbi.nlm.nih.gov/pubmed/29387478 http://dx.doi.org/10.1136/esmoopen-2017-000283

Ejemplares similares

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
por: Glitza Oliva, Isabella C., et al.
Publicado: (2023)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H, et al.
Publicado: (2018)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H., et al.
Publicado: (2019)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

SDPS-43 OUTCOMES OF SUPRATENTORIAL FOCAL ENHANCING LESIONS CONCERNING FOR LEPTOMENINGEAL METASTASES
por: Rodriguez, Andrew, et al.
Publicado: (2023)

Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted
por: Ballester, Leomar Y., et al.
Publicado: (2018)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Multidetector CT with 3-dimensional volume rendering in the evaluation of the spine in patients with Neurofibromatosis type 1: a retrospective review in 73 patients
por: Debnam, James Matthew, et al.
Publicado: (2014)

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report
por: Uemura, Marc, et al.
Publicado: (2016)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2016)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
por: Uemura, Marc, et al.
Publicado: (2017)

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes
por: Haymaker, Cara, et al.
Publicado: (2015)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Ventricular apparent diffusion coefficient measurements in patients with neoplastic leptomeningeal disease
por: Debnam, James M., et al.
Publicado: (2020)

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer
por: Sakellariou-Thompson, Donastas, et al.
Publicado: (2015)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Sloane, Robert A. Szczepaniak, et al.
Publicado: (2021)

Prognostic and biologic significance of high LCK expression in ovarian cancer
por: Jazaeri, Amir, et al.
Publicado: (2015)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

LPTO-09. INTRATHECAL TOPOTECAN FOR LEPTOMENINGEAL METASTASIS IN SOLID TUMORS: THE MD ANDERSON EXPERIENCE
por: Sinicrope, Kaylyn D, et al.
Publicado: (2019)

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017)

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity
por: Malu, Shruti, et al.
Publicado: (2013)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

Three-Dimensional Volume-Rendered Series Complements 2D Orthogonal Multidetector Computed Tomography in the Evaluation of Abnormal Spinal Curvature in Patients at a Major Cancer Center: A Retrospective Review
por: Debnam, J. Matthew, et al.
Publicado: (2012)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
por: Lu, Nu T., et al.
Publicado: (2015)

Pulsed Erlotinib as Sole Treatment of Leptomeningeal Carcinomatosis: Can We Avoid the Use of Intrathecal Therapy?
por: Santhosh-Kumar, Cheruppolil R., et al.
Publicado: (2014)

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
por: Geng, Di, et al.
Publicado: (2022)

Intrathecal methotrexate in combination with systemic chemotherapy in glioblastoma patients with leptomeningeal dissemination: A retrospective analysis
por: Kang, Xun, et al.
Publicado: (2022)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

Rheumatoid arthritis mimicking metastatic squamous cell carcinoma
por: Gomez-Rivera, Fernando, et al.
Publicado: (2011)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6ltn2s5h99vu7lohdcp65rdiqo